Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1250214 | 0.85 | EPHX2 (0.56) | XDHFFAR1EPHX2NR1H4 | |
| SCHEMBL1249240 | 0.83 | ADH5 (0.55) | XDHEPHX2NR1H4ALDH1A1 | |
| SCHEMBL1247935 | 0.80 | FFAR1 (0.55) | XDHFFAR1 | |
| SCHEMBL1287947 | 0.78 | HIF1A (0.83) | HIF1AMRGPRX4HDAC8HDAC6FFAR1 | |
| SCHEMBL1250233 | 0.78 | MAPT (0.58) | MAPTNR1H4ALDH1A1 | |
| SCHEMBL1249112 | 0.78 | KMT2A (0.62) | MAPTFFAR1ALDH1A1 | |
| SCHEMBL1250333 | 0.78 | ADH5 (0.56) | XDHFFAR1EPHX2NR1H4ALDH1A1 | |
| SCHEMBL940146 | 0.77 | GP6 (0.65) | XDHMAPTCSNK2A1ALDH1A1 | |
| SCHEMBL1247635 | 0.77 | XDH (0.62) | XDHMAPTNR1H4ALDH1A1 | |
| SCHEMBL16550428 | 0.76 | HIF1A (0.70) | HIF1AMRGPRX4HDAC8HDAC6FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1429763-B1 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-05-30 | — | — | EP | disclosed |
| US-20060258561-A1 | Novel NPH insulin preparations | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| EP-1605967-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| EP-1585541-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| CN-1558762-A | Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer | ŵ��Ų�ڿ˹�˾ | 2004-12-29 | — | — | CN | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| EP-1429763-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| WO-2003027081-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258561-A1 | Novel NPH insulin preparations | IAPP, HBB, INSR | HIF1A 4333/4885MRGPRX4 3810/4885HDAC8 1934/4885 |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | IAPP, IRS1, GPR119 | HIF1A 4532/4885MRGPRX4 2496/4885HDAC8 2584/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | HIF1A 4346/4885MRGPRX4 3099/4885HDAC8 1944/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | HIF1A 4738/4885MRGPRX4 3591/4885HDAC8 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.